BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16368945)

  • 1. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Oken MM; Marcus PM; Hu P; Beck TM; Hocking W; Kvale PA; Cordes J; Riley TL; Winslow SD; Peace S; Levin DL; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Dec; 97(24):1832-9. PubMed ID: 16368945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study.
    Tammemagi MC; Freedman MT; Pinsky PF; Oken MM; Hu P; Riley TL; Ragard LR; Berg CD; Prorok PC
    J Thorac Oncol; 2009 Jun; 4(6):710-21. PubMed ID: 19404219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.
    Pinsky PF; Kramer BS
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26483244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval lung cancers not detected on screening chest X-rays: How are they different?
    Kvale PA; Johnson CC; Tammemägi M; Marcus PM; Zylak CJ; Spizarny DL; Hocking W; Oken M; Commins J; Ragard L; Hu P; Berg C; Prorok P
    Lung Cancer; 2014 Oct; 86(1):41-6. PubMed ID: 25123333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute.
    Gohagan J; Marcus P; Fagerstrom R; Pinsky P; Kramer B; Prorok P;
    Chest; 2004 Jul; 126(1):114-21. PubMed ID: 15249451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.
    Oken MM; Hocking WG; Kvale PA; Andriole GL; Buys SS; Church TR; Crawford ED; Fouad MN; Isaacs C; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Rathmell JM; Riley TL; Wright P; Caparaso N; Hu P; Izmirlian G; Pinsky PF; Prorok PC; Kramer BS; Miller AB; Gohagan JK; Berg CD;
    JAMA; 2011 Nov; 306(17):1865-73. PubMed ID: 22031728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
    J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.
    Horeweg N; Scholten ET; de Jong PA; van der Aalst CM; Weenink C; Lammers JW; Nackaerts K; Vliegenthart R; ten Haaf K; Yousaf-Khan UA; Heuvelmans MA; Thunnissen E; Oudkerk M; Mali W; de Koning HJ
    Lancet Oncol; 2014 Nov; 15(12):1342-50. PubMed ID: 25282284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
    Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
    Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
    Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Church T; Yurgalevitch S; Austin JH; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Jul; 97(13):989-97. PubMed ID: 15998952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round.
    Pedersen JH; Ashraf H; Dirksen A; Bach K; Hansen H; Toennesen P; Thorsen H; Brodersen J; Skov BG; Døssing M; Mortensen J; Richter K; Clementsen P; Seersholm N
    J Thorac Oncol; 2009 May; 4(5):608-14. PubMed ID: 19357536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
    Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
    PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
    Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic evaluation following a positive lung screening chest radiograph in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Tammemagi MC; Commins J; Oken MM; Kvale PA; Hu P; Ragard LR; Riley TL; Pinsky P; Beck TM; Prorok PC
    Lung Cancer; 2013 Nov; 82(2):238-44. PubMed ID: 23993734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).
    Fasola G; Belvedere O; Aita M; Zanin T; Follador A; Cassetti P; Meduri S; De Pangher V; Pignata G; Rosolen V; Barbone F; Grossi F
    Oncologist; 2007 Oct; 12(10):1215-24. PubMed ID: 17962615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.
    Tammemagi CM; Pinsky PF; Caporaso NE; Kvale PA; Hocking WG; Church TR; Riley TL; Commins J; Oken MM; Berg CD; Prorok PC
    J Natl Cancer Inst; 2011 Jul; 103(13):1058-68. PubMed ID: 21606442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.